|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA25
|
|
gptkbp:blackBoxWarning
|
meningococcal infection risk
|
|
gptkbp:CASNumber
|
219685-50-4
|
|
gptkbp:contraindication
|
active meningococcal infection
|
|
gptkbp:developedBy
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:eculizumab
|
|
gptkbp:halfLife
|
270-375 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Soliris
|
|
gptkbp:indication
|
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:atypical_hemolytic_uremic_syndrome
gptkb:neuromyelitis_optica_spectrum_disorder
generalized myasthenia gravis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
complement inhibitor
|
|
gptkbp:molecularWeight
|
148 kDa
|
|
gptkbp:origin
|
humanized
|
|
gptkbp:patentExpired
|
2027 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:priceRange
|
one of the most expensive drugs
|
|
gptkbp:PubChem_CID
|
gptkb:DB01257
|
|
gptkbp:requiresVaccination
|
gptkb:meningococcal_vaccine
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
headache
hypertension
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:C5_protein
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:UNII
|
8Q2K6F1K73
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|